AgomAb Therapeutics NV (AGMB)
NASDAQ: AGMB · Real-Time Price · USD
10.98
+0.88 (8.71%)
At close: Jun 18, 2026, 4:00 PM EDT
11.29
+0.31 (2.82%)
After-hours: Jun 18, 2026, 7:59 PM EDT
AgomAb Therapeutics NV Employees
AgomAb Therapeutics NV had 62 employees as of December 31, 2025. The number of employees increased by 4 or 7.27% compared to the previous year.
Employees
62
Change (1Y)
4
Growth (1Y)
7.27%
Revenue / Employee
n/a
Profits / Employee
-$1,467,672
Market Cap
540.74M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 62 | 4 | 7.27% |
| Dec 31, 2024 | 58 | 24 | 70.00% |
| Dec 31, 2023 | 34 | 33 | 3,300.00% |
| Dec 31, 2019 | 1 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| MiMedx Group | 808 |
| Valneva SE | 674 |
| Gyre Therapeutics | 625 |
| ProKidney | 231 |
| 4D Molecular Therapeutics | 196 |
| Prime Medicine | 146 |
| Rezolute | 68 |
| Tectonic Therapeutic | 60 |
AGMB News
- 25 days ago - Agomab Announces Results of Annual General Meeting - GlobeNewsWire
- 5 weeks ago - Agomab to Participate in Upcoming Conferences - GlobeNewsWire
- 2 months ago - Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook - GlobeNewsWire
- 2 months ago - AgomAb Therapeutics NV Earnings release: Q4 2025 - Filings
- 2 months ago - AgomAb Therapeutics NV Annual report: Q4 2025 - Filings
- 3 months ago - Agomab receives U.S. patent for AGMB-447 - TheFly
- 3 months ago - Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis - GlobeNewsWire
- 3 months ago - Agomab initiated with an Outperform at Leerink - TheFly